We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ - Free Report) . Shares have added about 1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Jazz due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Jazz Pharmaceuticals PLC before we dive into how investors and analysts have reacted as of late.
Q1 Earnings & Sales Beat Estimates
Jazz Pharmaceuticals reported first-quarter 2026 adjusted earnings per share (EPS) of $6.34, which beat the Zacks Consensus Estimate of $4.67. In the year-ago quarter, the company posted EPS of $1.68, which was significantly impacted by higher operating expenses.
Total revenues rose 19% year over year to $1.07 billion, which beat the Zacks Consensus Estimate of $972 million.
Quarter in Detail
Net product sales increased 22% year over year to $1.03 billion. The reported figure beat both the Zacks Consensus Estimate of $925 million and our model estimate of $924 million.
Jazz recorded about $36.3 million in royalty revenues from high-sodium oxybate authorized generic (AG), down about 26% year over year.
Other royalties and contract revenues declined 23% to $7.3 million.
Neuroscience Products
Net product sales for the combined oxybate business (Xyrem + Xywav) rose 15% to $439.4 million. This combined figure beat both the Zacks Consensus Estimate of $390 million and our model estimates of $393 million.
Sales of Xyrem declined 16% year over year to $31.2 million due to patients switching to Xywav and the launch of AGs in 2023.
Xywav recorded sales of $408.2 million in the quarter, up 18%. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and IH indications. This drug is currently Jazz’s most extensive product by net sales.
Sales of Epidiolex/Epidyolex rose 15% to $249.8 million, driven by continued strong demand. This metric also beat the Zacks Consensus Estimate of $238 million and our model estimate of $234 million.
Oncology Products
Oncology product sales rose 45% to $333.4 million.
Rylaze/Enrylaze posted sales of $103.7 million, up 10% year over year. This figure beat the Zacks Consensus Estimate and our model estimate, each pegged at $97 million.
Zepzelca recorded sales of $101 million, up 60% year over year. This upside was primarily driven by continued uptake of the drug in the recently approved front-line SCLC setting.
Vyxeos generated sales of $26.6 million, down 10%. Defitelio sales rose more than 16% to $47.4 million.
Ziihera added $13.3 million to the top line compared with $8.5 million in the previous quarter.
Jazz recorded revenues worth $41.4 million from the sales of its recently launched Modeyso, compared to $36.5 million in the previous quarter.
Cost Discussion
Adjusted selling, general and administrative expenses (SG&A) declined 35% year over year to $308.5 million. This downtick was primarily attributed to certain Xyrem antitrust litigation settlements worth $172 million incurred in the year-ago period.
Adjusted research and development (R&D) expenses rose 8% to $172.3 million, mainly due to the addition of costs relating to Modeyso incurred during the quarter.
Reiterates 2026 Guidance
Total revenues are expected to be in the range of $4.25-$4.50 billion, suggesting 2.5% year-over-year growth at the midpoint compared with the 2025 level.
While adjusted SG&A expenses are anticipated to be between $1.26 billion and $1.32 billion, adjusted R&D expenses are expected to be in the range of $725-$775 million.
The effective tax rate is expected to be between 11.5% and 13.5%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Jazz has a great Growth Score of A, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Jazz has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Jazz belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vertex Pharmaceuticals (VRTX - Free Report) , has gained 0.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Vertex reported revenues of $2.99 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $4.47 for the same period compares with $4.06 a year ago.
Vertex is expected to post earnings of $4.79 per share for the current quarter, representing a year-over-year change of +6%. Over the last 30 days, the Zacks Consensus Estimate has changed -1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Vertex. Also, the stock has a VGM Score of D.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ - Free Report) . Shares have added about 1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Jazz due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Jazz Pharmaceuticals PLC before we dive into how investors and analysts have reacted as of late.
Q1 Earnings & Sales Beat Estimates
Jazz Pharmaceuticals reported first-quarter 2026 adjusted earnings per share (EPS) of $6.34, which beat the Zacks Consensus Estimate of $4.67. In the year-ago quarter, the company posted EPS of $1.68, which was significantly impacted by higher operating expenses.
Total revenues rose 19% year over year to $1.07 billion, which beat the Zacks Consensus Estimate of $972 million.
Quarter in Detail
Net product sales increased 22% year over year to $1.03 billion. The reported figure beat both the Zacks Consensus Estimate of $925 million and our model estimate of $924 million.
Jazz recorded about $36.3 million in royalty revenues from high-sodium oxybate authorized generic (AG), down about 26% year over year.
Other royalties and contract revenues declined 23% to $7.3 million.
Neuroscience Products
Net product sales for the combined oxybate business (Xyrem + Xywav) rose 15% to $439.4 million. This combined figure beat both the Zacks Consensus Estimate of $390 million and our model estimates of $393 million.
Sales of Xyrem declined 16% year over year to $31.2 million due to patients switching to Xywav and the launch of AGs in 2023.
Xywav recorded sales of $408.2 million in the quarter, up 18%. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and IH indications. This drug is currently Jazz’s most extensive product by net sales.
Sales of Epidiolex/Epidyolex rose 15% to $249.8 million, driven by continued strong demand. This metric also beat the Zacks Consensus Estimate of $238 million and our model estimate of $234 million.
Oncology Products
Oncology product sales rose 45% to $333.4 million.
Rylaze/Enrylaze posted sales of $103.7 million, up 10% year over year. This figure beat the Zacks Consensus Estimate and our model estimate, each pegged at $97 million.
Zepzelca recorded sales of $101 million, up 60% year over year. This upside was primarily driven by continued uptake of the drug in the recently approved front-line SCLC setting.
Vyxeos generated sales of $26.6 million, down 10%. Defitelio sales rose more than 16% to $47.4 million.
Ziihera added $13.3 million to the top line compared with $8.5 million in the previous quarter.
Jazz recorded revenues worth $41.4 million from the sales of its recently launched Modeyso, compared to $36.5 million in the previous quarter.
Cost Discussion
Adjusted selling, general and administrative expenses (SG&A) declined 35% year over year to $308.5 million. This downtick was primarily attributed to certain Xyrem antitrust litigation settlements worth $172 million incurred in the year-ago period.
Adjusted research and development (R&D) expenses rose 8% to $172.3 million, mainly due to the addition of costs relating to Modeyso incurred during the quarter.
Reiterates 2026 Guidance
Total revenues are expected to be in the range of $4.25-$4.50 billion, suggesting 2.5% year-over-year growth at the midpoint compared with the 2025 level.
While adjusted SG&A expenses are anticipated to be between $1.26 billion and $1.32 billion, adjusted R&D expenses are expected to be in the range of $725-$775 million.
The effective tax rate is expected to be between 11.5% and 13.5%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Jazz has a great Growth Score of A, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Jazz has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Jazz belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vertex Pharmaceuticals (VRTX - Free Report) , has gained 0.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Vertex reported revenues of $2.99 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $4.47 for the same period compares with $4.06 a year ago.
Vertex is expected to post earnings of $4.79 per share for the current quarter, representing a year-over-year change of +6%. Over the last 30 days, the Zacks Consensus Estimate has changed -1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Vertex. Also, the stock has a VGM Score of D.